To determine if arrhythmias, such as ventricular tachycardia (VT), are unstable and require an electric shock, physicians determine whether the heart can still maintain adequate forward output of blood. For patients with an Implantable Cardioverter Defibrillator (ICD), forward blood output information is not available in order to determine if a shock is required. This is done by algorithmic interpretation of ECG (electrical) data from the pacemaker. Without the benefit of blood flow (hemodynamic) data, this sometimes results in unnecessary electric shocks.


It has been reported that up to 1/3 of patients who receive an ICD will experience an “appropriate” shock within the first 1-3 years of receiving the implant. Around a third of patients receive an “inappropriate” shock, indicating that therapy was delivered unnecessarily, and the remaining third do not receive a shock. Receiving a shock is associated with a two- to five- fold increase in mortality in these patients, so the elimination of unnecessary shocks has become an important focus in ICD research within the last decade.


The benefits of Admittance Technology’s hemodynamic (SV) monitoring technology will be threefold:

  1. Battery life could be conserved with the prevention of inappropriate shocks, reducing the need for post-implant surgery to replace the battery
  2. Unnecessary trauma to the patient’s heart could be prevented, because shocks are correlated with mortality
  3. Patients’ quality of life could improve by reducing fear associated with unnecessary shocks